TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

作者: Dorota Jesionek-Kupnicka , Malgorzata Szybka , Beata Malachowska , Wojciech Fendler , Piotr Potemski

DOI: 10.1089/DNA.2013.2201

关键词: Messenger RNADNA methylationEpigenetics of physical exerciseBiologyEpigeneticsMethylationMolecular biologyGene silencingGeneCancer researchMutation

摘要: Reduced expression of TP53 by promoter methylation has been reported in several neoplasms. It remains unclear whether is associated with reduced transcriptional and protein glioblastoma (GB). The aim our work was to study the impact mutations on mRNA level 42 molecularly characterized primary GB tumors. We also evaluate all molecular alterations overall patient survival. frequency found 21.4%. To best knowledge, this first report showing such high GB. There no relation between (p=0.5722) (p=0.2045). No significant associations were mutation gene (p=0.9076). However, association (p=0.0016). Our data suggest that does not play a role silencing probably regulated other genetic epigenetic mechanisms genes involved pathway.

参考文章(58)
M. Szybka, J. Z. Błoński, Piotr Rieske, Ewa Golańska, Jacek Bartkowiak, T. Robak, Izabela Wójcik, Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma. ,vol. 52, pp. 318- 324 ,(2005)
Hiroko Ohgaki, Paul Kleihues, Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Journal of Neuropathology and Experimental Neurology. ,vol. 64, pp. 479- 489 ,(2005) , 10.1093/JNEN/64.6.479
B. Bienz-Tadmor, R. Zakut-Houri, S. Libresco, D. Givol, M. Oren, The 5' region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. The EMBO Journal. ,vol. 4, pp. 3209- 3213 ,(1985) , 10.1002/J.1460-2075.1985.TB04067.X
K Ichimura, Maria Bondesson Bolin, Helena M Goike, Esther E Schmidt, Ahmad Moshref, V Peter Collins, Deregulation of the p14ARF/MDM2/p53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G1-S Transition Control Gene Abnormalities Cancer Research. ,vol. 60, pp. 417- 424 ,(2000)
Pilar Gonzalez-Gomez, Dolores Arjona, Alberto Isla, M. Eva Alonso, Jesus Lomas, Jose M. De Campos, M. Josefa Bello, Jesus Vaquero, Juan A. Rey, Manuel Gutierrez, Promoter hypermethylation of multiple genes in astrocytic gliomas. International Journal of Oncology. ,vol. 22, pp. 601- 608 ,(2003) , 10.3892/IJO.22.3.601
S P Tuck, L Crawford, Characterization of the human p53 gene promoter. Molecular and Cellular Biology. ,vol. 9, pp. 2163- 2172 ,(1989) , 10.1128/MCB.9.5.2163
Junko Hirato, Keisuke Ueki, Takamitsu Fujimaki, Takaaki Kirino, Takafumi Ide, Nobuaki Funada, Ryo Nishikawa, Akitake Mukasa, Takanori Hirose, Masaaki Usui, Shuntaro Hojo, Yoichi Nakazato, Shoichi Ito, Akio Asai, Osami Kubo, Chikayuki Ochiai, Hiroshi Takahashi, Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors Clinical Cancer Research. ,vol. 8, pp. 196- 201 ,(2002)
Bert Vogelstein, David Sidransky, Ruth W. Craig, Michael B. Kastan, Onyinye Onyekwere, Participation of p53 Protein in the Cellular Response to DNA Damage Cancer Research. ,vol. 51, pp. 6304- 6311 ,(1991)
Xinjiang Wang, Junru Wang, Xuejun Jiang, MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination Journal of Biological Chemistry. ,vol. 286, pp. 23725- 23734 ,(2011) , 10.1074/JBC.M110.213868
Amandine Etcheverry, Marc Aubry, Marie de Tayrac, Elodie Vauleon, Rachel Boniface, Frederique Guenot, Stephan Saikali, Abderrahmane Hamlat, Laurent Riffaud, Philippe Menei, Veronique Quillien, Jean Mosser, DNA methylation in glioblastoma: impact on gene expression and clinical outcome BMC Genomics. ,vol. 11, pp. 701- 701 ,(2010) , 10.1186/1471-2164-11-701